Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
Randa Bascharon, Founder, President and Orthopedic Surgeon at Sports Performance Institute of Las Vegas, shared a post on LinkedIn:
“Wharton’s Jelly is increasingly discussed in orthopedic and sports medicine settings, particularly among active patients looking for non-surgical options.
Wharton’s Jelly is derived from donated umbilical cord tissue and contains growth factors and signaling proteins that may support the body’s healing environment.
In clinical practice, it is considered in select cases involving tendon injuries, ligament issues, or certain joint conditions.
A few practical points are important:
- First, it is not the same as a steroid injection.
- Second, it is different from platelet-rich plasma.
- Third, it is not a universal substitute for surgery.
Candidacy varies.
The decision to consider a biologic injection depends on the diagnosis, severity of tissue damage, functional goals, prior treatments, and imaging findings.
Thoughtful patient selection matters.
For athletes and active adults, the real question is not whether a treatment is popular.
It is whether it aligns with the biology of their specific injury and their long-term performance goals.
If you are seeing more patients ask about biologics, how are you approaching education and expectation setting in your practice?
Educational only.
A diagnosis and treatment plan require an in-person evaluation.”
See more in the gallery.
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers